Markets

Insider Trading

Hedge Funds

Retirement

Opinion

These 5 Stocks Under $10 Are Poised To Explode

In this piece, we will take a look at these 5 stocks under $10 are poised to explode. If you want to read our introduction to these tricky stocks, jump to These Stocks under $10 Are Poised To Explode.

5. Spire Global, Inc. (NYSE:SPIR

Share Price as of December 14: $7.52
Share Price Upside Potential: 249.16%
Number of Hedge Funds: 5

Spire Global, Inc. (NYSE:SPIR) is one of the cheap stocks under $10 for anyone eyeing exposure in the industrial sector. Spire Global, Inc. (NYSE:SPIR) provides subscription-based data insights, predictive insights, and related project-based services. It also offers satellite-based aircraft tracking data to power applications and drive decision-making.

Spire Global, Inc. (NYSE:SPIR)’s sentiments have improved in the last quarter of the year after coming under pressure for the first nine months. It is up by more than 100% in the fourth quarter as analysts reiterate a consensus Buy rating with a $25 price target implying 249.16% upside potential.

Insider Monkey’s Q3 2023 survey of 910 hedge funds outlined that 5 had bought Spire Global, Inc. (NYSE:SPIR)’s shares.

Follow Spire Corp (NYSE:SPIR)

[/company-follow-email]

4. Caribou Biosciences, Inc. (NASDAQ:CRBU)

Share Price as of December 14: $6.41
Share Price Upside Potential: 289.38%
Number of Hedge Funds: 21

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company that develops genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors. Caribou Biosciences, Inc. (NASDAQ:CRBU)’s lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

Caribou Biosciences, Inc. (NASDAQ:CRBU) has recouped a significant chunk of the losses accrued in the year and is only down by 10%. The consensus rating on Wall Street is a Buy with a $22 price target, implying 289.38% upside potential. According to Insider Monkey’s third-quarter database, 21 hedge funds were long Caribou Biosciences, Inc. (NASDAQ:CRBU), compared to 15 funds in the last quarter.

Follow Caribou Biosciences Inc. (NASDAQ:CRBU)

[/company-follow-email]

3. Aqua Metals Inc. (NASDAQ:AQMS)

Share Price as of December 14: $0.90
Share Price Upside Potential: 330.25%
Number of Hedge Funds: 1

Aqua Metals Inc. (NASDAQ:AQMS) is another cheap stock under $10 poised to explode for diversifying an investment portfolio into the Industrials sector. Aqua Metals Inc. (NASDAQ:AQMS) recycles materials that are essential for making energy storage and electric vehicle products.

The consensus rating on Aqua Metals Inc. (NASDAQ:AQMS) is a Buy with a $4 price target, implying a 330.25% upside potential from current levels. By the end of this year’s third quarter, 1 out of the 910 hedge funds polled by Insider Monkey had owned Aqua Metals Inc. (NASDAQ:AQMS)’s shares.

Follow Aqua Metals Inc. (NASDAQ:AQMS)

[/company-follow-email]

2. AST SpaceMobile, Inc. (NASDAQ:ASTS)

Share Price as of December 14: $5.24
Share Price Upside Potential: 351.87%
Number of Hedge Funds: 9

AST SpaceMobile, Inc. (NASDAQ:ASTS) is a technology company and one of the cheap stocks under $10 poised to explode. AST SpaceMobile, Inc. (NASDAQ:ASTS) and its subsidiaries operate a space-based cellular broadband network for mobile phones. 

AST SpaceMobile, Inc. (NASDAQ:ASTS) is up by about 5.3% as it recoups the losses accrued for the rest of the year. The consensus analysts’ ratings on Wall Street are a Buy with a $23 price target, implying a 351.87% upside potential from current levels. The bullishness comes from one of AST SpaceMobile, Inc. (NASDAQ:ASTS)’s insiders, who have raised stakes by 404% over the past 12 months.

Insider Monkey’s Q3 2023 survey of 910 hedge funds outlined that nine had invested in AST SpaceMobile, Inc. (NASDAQ:ASTS).

Follow Ast Spacemobile Inc. (NASDAQ:ASTS)

[/company-follow-email]

1. Anavex Life Sciences Corp. (NASDAQ:AVXL

Share Price as of December 14: $8.45
Share Price Upside Potential: 596.52%
Number of Hedge Funds: 9

Anavex Life Sciences Corp. (NASDAQ:AVXL) is a clinical-stage biopharmaceutical company that develops therapeutics for treating central nervous system diseases. Anavex Life Sciences Corp. (NASDAQ:AVXL)’s lead product is Anavex, which is used for the treatment of Alzheimer’s disease, Parkinson’s disease, and other central nervous system illnesses.

While Anavex Life Sciences Corp. (NASDAQ:AVXL) is down by 18%, it commands a consensus Buy rating on Wall Street with a $56 price target, implying a 596.52% upside potential. Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the stocks under $10 poised to explode, going by its ambitions in developing treatment options for Alzheimer’s.

At the end of the third quarter of 2023, 9 hedge funds from our database held stakes in Anavex Life Sciences Corp. (NASDAQ:AVXL). The total value of these positions amounted to approximately $10.35 million.

Follow Anavex Life Sciences Corp. (NASDAQ:AVXL)

[/company-follow-email]

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily newsletter to get  the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out our articles on 12 Best Growth Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates and Billionaire Paul Singer’s Recent Activist Targets and Top Stock Picks.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.